參考文獻(xiàn)/References:
[1] 中華醫(yī)學(xué)會(huì)血液學(xué)分會(huì)血栓與止血學(xué)組、中國(guó)血友病協(xié)作組.血友病診斷與治療中國(guó)專(zhuān)家共識(shí)(2017年版)[J].中華血液學(xué)雜志,2016,37(5):364-370.
[2] BHARDWAJ R,RATH G,GOYAL A K.Advancement in the treatment of haemophilia[J].Int J Biol Macromol,2018,118(Pt A):289-295.
[3] HANLEY J,MCKERNAN A,CREAGH M D,et al.Guidelines for the management of acute joint bleeds and chronic synovitis in haemophilia:a United Kingdom Haemophilia Centre Doctors’ Organisation(UKHCDO)guideline[J].Haemophilia,2017,23(4):511-520.
[4] KASHIWAKURA Y,OHMORI T,MIMURO J,et al.Intra-articular injection of mesenchymal stem cells expressing coagulation factor ameliorates hemophilic arthropathy in factor Ⅷ-deficient mice[J].J Thromb Haemost,2012,10(9):1802-1813.
[5] RODRIGUEZ-MERCHAN E C.Intra-articular injections of mesenchymal stem cells(MSCs)as a treatment for hemophilic arthropathy[J].Expert Rev Hematol,2016,9(8):737-741.
[6] VANNABOUATHONG C,DEL FABBRO G,SALES B,et al.Intra-articular injections in the treatment of symptoms from ankle arthritis:a systematic review[J].Foot Ankle Int,2018,39(10):1141-1150.
[7] OHMORI T,MIZUKAMI H,KATAKAI Y,et al.Safety of intra-articular transplantation of lentivirally transduced mesenchymal stromal cells for haemophilic arthropathy in a non-human primate[J].Int J Hematol,2018,108(3):239-245.
[8] MATSUI H,SHIBATA M,BROWN B,et al.Ex vivo gene therapy for hemophilia A that enhances safe delivery and sustained in vivo factor Ⅷ expression from lentivirally engineered endothelial progenitors[J].Stem Cells,2007,25(10):2660-2669.
[9] FOMIN M E,TOGARRATI P P,MUENCH M O.Progress and challenges in the development of a cell-based therapy for hemophilia A[J].J Thromb Haemost,2014,12(12):1954-1965.
[10] LYU C,SHEN J,WANG R,et al.Targeted genome engineering in human induced pluripotent stem cells from patients with hemophilia B using the CRISPR-Cas9 system[J].Stem Cell Res Ther,2018,9(1):92.
[11] 王大威.基于干細(xì)胞的靶向血小板基因治療血友病A的研究[D].上海:上海交通大學(xué),2017.
[12] YOSHIHARA M,OGUCHI A,MURAKAWA Y.Genomic instability of iPSCs and challenges in their clinical applications[J].Adv Exp Med Biol,2019,1201:23-47.
[13] VASKO T,FROBEL J,LUBBERICH R,et al.IPSC-derived mesenchymal stromal cells are less supportive than primary MSCs for co-culture of hematopoietic progenitor cells[J].J Hematol Oncol,2016,9:43.
[14] 王韻,施小鳳,毛建華,等.靶向血小板表達(dá)FⅧ基因治療血友病A的新進(jìn)展[J].國(guó)際輸血及血液學(xué)雜志,2020,43(1):17-22.
[15] BAUMGARTNER C K,MATTSON J G,WEILER H,et al.Targeting factor Ⅷexpression to platelets for hemophilia A gene therapy does not induce an apparent thrombotic risk in mice[J].J Thromb Haemost,2017,15(1):98-109.
[16] NATHWANI A C,TUDDENHAM E G,RANGARAJAN S,et al.Adenovirus-associated virus vector-mediated gene transfer in hemophilia B[J].N Engl J Med,2011,365(25):2357-2365.
[17] IORIO A,HALIMEH S,HOLZHAUER S,et al.Rate of inhibitor development in previously untreated hemophilia a patients treated with plasma-derived or recombinant factorⅧconcentrates:a systematic review[J].J Thromb Haemost,2010,8(6):1256-1265.
[18] BUNTING S,ZHANG L,XIE L,et al.Gene therapy with BMN 270 results in therapeutic levels of FⅧ in mice and primates and normalization of bleeding in hemophilic mice[J].Mol Ther,2018,26(2):496-509.
[19] LONG B R,VERON P,KURANDA K,et al.Early phase clinical immunogenicity of valoctocogene roxaparvovec,an AAV5-mediated gene therapy for hemophilia A[J].Mol Ther,2021,29(2):597-610.
[20] AGBOOLA F,RIND D M,WALTON S M,et al.The effectiveness and value of emicizumab and valoctocogene roxaparvovec for the management of hemophilia A without inhibitors[J].J Manag Care Spec Pharm,2021,27(5):667-673.
[21] NIJDAM A,FOPPEN W,VAN DER SCHOUW Y T,et al.Long-term effects of joint bleeding before starting prophylaxis in severe haemophilia[J].Haemophilia,2016,22(6):852-858.
[22] KASHIWAKURA Y,OHMORI T,MIMURO J,et al.Intra-articular injection of mesenchymal stem cells expressing coagulation factor ameliorates hemophilic arthropathy in factor Ⅷdeficient mice[J].J Thromb Haemost,2012,10(9):1802-1813.
[23] 王志偉,索海強(qiáng),梁寒光,等.不同來(lái)源的間充質(zhì)干細(xì)胞在早期骨關(guān)節(jié)炎中治療的特點(diǎn)比較及展望[J].中華老年骨科與康復(fù)電子雜志,2020,6(6):364-369.
[24] PULLES A E,MASTBERGEN S C,SCHUTGENS R E,et al.Pathophysiology of hemophilic arthropathy and potential targets for therapy[J].Pharmacol Res,2017,115:192-199.
[25] JIANG W,XU J.Immune modulation by mesenchymal stem cells[J].Cell Prolif,2020,53(1):e12712.
[26] KRAMPERA M.Mesenchymal stromal cell “icensing”:a multistep process[J].Leukemia, 2011,25(9):1408-1414.
[27] NAUTA A J,KRUISSELBRINK A B,LURVINK E,et al.Mesenchymal stem cells inhibit generation and function of both CD34+-derived and monocyte-derived dendritic cells[J].J Immunol,2006,177(4):2080-2087.
[28] ABUMAREE M H,AL JUMAH M A,KALIONIS B,et al.Human placental mesenchymal stem cells(pMSCs)play a role as immune suppressive cells by shifting macrophage differentiation from inflammatory M1 to anti-inflammatory M2 macrophages[J].Stem Cell Rev Rep,2013,9(5):620-641.
[29] CHOI H, LEE R H,BAZHANOV N,et al.Anti-inflammatory protein TSG-6 secreted by activated MSCs attenuates zymosan-induced mouse peritonitis by decreasing TLR2/NF-κB signaling in resident macrophages[J].Blood,2011,118(2):330-338.
[30] 張純希,李想,周鈺翔,等.骨骼微環(huán)境中誰(shuí)決定間充質(zhì)干細(xì)胞的分化命運(yùn)[J].中國(guó)組織工程研究,2021,25(25):4045-4052.
[31] HUANG G,LI F,ZHAO X,et al.Functional and biomimetic materials for engineering of the three-dimensional cell microenvironment[J].Chem Rev,2017,117(20):12764-12850.
[32] ZHANG S,CHUAH S J,LAI R C,et al.MSC exosomes mediate cartilage repair by enhancing proliferation,attenuating apoptosis and modulating immune reactivity[J].Biomaterials,2018,156:16-27.
[33] GURUNATHAN S,KANG M H,JEYARAJ M,et al.Review of the isolation,characterization,biological function,and multifarious therapeutic approaches of exosomes[J].Cells,2019,8(4):307.
[34] GANGADHARAN B,PARKER E T,IDE L M, et al.High-level expression of porcine factor Ⅷ from genetically modified bone marrow-derived stem cells[J].Blood,2006,107(10):3859-3864.
相似文獻(xiàn)/References:
[1]鄧偉哲,王宏晶,王宇恒,等.微創(chuàng)針刀鏡治療難治性膝關(guān)節(jié)類(lèi)風(fēng)濕關(guān)節(jié)炎[J].中醫(yī)正骨,2015,27(11):42.
[2]李藝彬,朱勇,吳昭克.關(guān)節(jié)鏡下多入路全關(guān)節(jié)滑膜清理術(shù)治療肘關(guān)節(jié)類(lèi)風(fēng)濕關(guān)節(jié)炎[J].中醫(yī)正骨,2015,27(11):56.
[3]齊新宇,向黎黎,熊輝,等.基于高蛋白飲食建立雞痛風(fēng)性關(guān)節(jié)炎模型的量效關(guān)系研究[J].中醫(yī)正骨,2015,27(02):1.
QI Xinyu,XIANG Lili,XIONG Hui,et al.A dose-effect relationship study of gouty arthritis chicken model built by high-protein diet[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(07):1.
[4]齊新宇,熊輝,周彪,等.蠲痹歷節(jié)清方干預(yù)雞急性痛風(fēng)性關(guān)節(jié)炎模型的
實(shí)驗(yàn)研究[J].中醫(yī)正骨,2015,27(03):5.
QI Xinyu,XIONG Hui,ZHOU Biao,et al.Juanbilijieqing Fang(蠲痹歷節(jié)清方)interfere with acute gouty arthritis chiken model[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(07):5.
[5]胡鋼鋒,肖魯偉,童培建.關(guān)節(jié)液代謝組學(xué)在類(lèi)風(fēng)濕關(guān)節(jié)炎診斷
及寒熱證候分型中的應(yīng)用[J].中醫(yī)正骨,2015,27(01):5.
HU Gangfeng,XIAO Luwei,TONG Peijian.Application of joint fluid metabolomics to diagnosis and COLD-HEAT SYMPTOM COMPLEX typing in patients with rheumatoid arthritis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(07):5.
[6]熊輝,曲良燁,向黎黎,等.痛風(fēng)性關(guān)節(jié)炎濕熱證病證結(jié)合模型的建立[J].中醫(yī)正骨,2014,26(03):14.
Xiong Hui*,Qu Liangye,Xiang Lili,et al.A rat model of gouty arthritis combined with dampness-heat syndrome[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2014,26(07):14.
[7]孫克民,王平,盧啟貴,等.關(guān)節(jié)鏡下滑膜切除術(shù)聯(lián)合中藥口服
治療早期膝關(guān)節(jié)類(lèi)風(fēng)濕關(guān)節(jié)炎[J].中醫(yī)正骨,2013,25(09):39.
[8]李峰,郭艷幸,曹向陽(yáng),等.貫葉連翹灌胃聯(lián)合光動(dòng)力療法對(duì)類(lèi)風(fēng)濕關(guān)節(jié)炎白兔膝關(guān)節(jié)滑膜組織病理形態(tài)的影響[J].中醫(yī)正骨,2014,26(09):6.
Li Feng*,Guo Yanxing,Cao Xiangyang,et al.Effect of intragastric administration of hypericum perforatum combined with photodynamic therapy on the pathological morphology of synovial tissue of knee joints in rabbits with rheumatoid arthritis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2014,26(07):6.
[9]嚴(yán)超,劉喜德,張金祿,等.蜂針療法治療膝骨性關(guān)節(jié)炎的護(hù)理[J].中醫(yī)正骨,2013,25(01):74.
[10]王笑青,張永紅,侯宏理,等.頑痹清丸聯(lián)合非甾體抗炎藥及改善病情的抗風(fēng)濕藥治療濕熱痹阻型類(lèi)風(fēng)濕關(guān)節(jié)炎[J].中醫(yī)正骨,2013,25(03):41.
WANG Xiao-qing*,ZHANG Yong-hong,HOU Hong-li,et al.Curative effect and safety of WANBIQING pills combined with nonsteroidal antiinflammatory drugs and disease modifying antirheumatic drugs in the treatment of rheumatoid arthritis of dampness-heat stagnation type[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2013,25(07):41.
[11]王彭禾,汪小健,吳叢姿,等.血友病性關(guān)節(jié)炎與骨質(zhì)疏松癥的關(guān)系研究[J].中醫(yī)正骨,2022,34(02):31.
.The First Clinical Medical College of Zhejiang Chinese Medical University,Hangzhou 00,Zhejiang,et al.WANG Penghe1,WANG Xiaojian1,WU Congzi1,SHI Zhenyu1,JIN Hongting1,WANG Pinger1,TONG Peijian2[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2022,34(07):31.